March 15, 2022
RegMed Investors’ (RMi) pre-open: cell and gene therapy sector, not lookin’ good
March 14, 2022
RegMed Investors’ (RMi) pre-open: the phoenix rises from the shares as do share pricings after being burned to a crisp
March 11, 2022
RegMed Investors’ (RMi) pre-open: dramatic market and sector moves are still questionable
March 10, 2022
RegMed Investors’ (RMi) pre-open: time to take some chips off the table
March 9, 2022
RegMed Investors’ (RMi) pre-open: tread lightly, add, trim or hedge as needed
March 8, 2022
RegMed Investors’ (RMi) pre-open: will algorithms push an upside bounce response
March 7, 2022
RegMed Investors’ (RMi) pre-open: risk-on is back in play
March 4, 2022
RegMed Investors’ (RMi) pre-open: scary markets out-there, careful as you go
March 3, 2022
RegMed Investors’ (RMi) pre-open: on the gene editing merry-go-round
March 2, 2022
RegMed Investors’ (RMi) pre-open: after a sell-off, a pop and a profit mode?
March 1, 2022
RegMed Investors’ (RMi) pre-open: a volatile, earnings and headline driven sector and market
February 28, 2022
RegMed Investors’ (RMi) pre-open: Again, I ask what’s sustainable in this warring geo-political turmoil?
February 25, 2022
RegMed Investors’ (RMi) pre-open: turning or burning - the sector correction beyond the invasion of Ukraine
February 24, 2022
RegMed Investors’ (RMi) pre-open: the invasion/attack has begun shaking global markets
February 23, 2022
RegMed Investors’ (RMi) pre-open: overcoming resistance to instill a little lost confidence
February 22, 2022
RegMed Investors’ (RMi) pre-open: rolling in chaos and uncertainty
February 18, 2022
RegMed Investors’ (RMi) pre-open: a dry-up in liquidity
February 17, 2022
RegMed Investors’ (RMi) pre-open: damaged goods or is it time to consider near-term intentions?
February 16, 2022
RegMed Investors’ (RMi) pre-open: what’s sustainable share pricing in our universe of cell and gene therapy?
February 15, 2022
RegMed Investors’ (RMi) pre-open: a tailwind of sharply higher futures due to past headlines
February 14, 2022
RegMed Investors’ (RMi) pre-open: the new year and February have been painful, and now agonizing Q4/FY21 earnings
February 11, 2022
RegMed Investors’ (RMi) pre-open: put a cork in the cell and gene therapy bottle before trading evaporates the contents
February 10, 2022
RegMed Investors’ (RMi) pre-open: sector earnings and inflation data releases are on tap
February 9, 2022
RegMed Investors’ (RMi) pre-open: closer and closer, come sector earnings
February 8, 2022
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.